Cary, N.C. , Jan. 2, 2026 – Biologics by McKesson’s Pharmacy Elite™, has been awarded the Rigel Pharmaceuticals Hub contract to serve as the central patient services hub for their therapies: TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib).
As Rigel’s designated Hub, Pharmacy Elite™ provides patient- and provider-focused services which simplify access to therapy. These services include benefits investigation, financial assistance navigation, and prior authorization support, as well as eligibility validation for patients enrolled in assistance programs.
“We are honored to strengthen our relationship with Rigel as the Hub for these vital therapies, working together to deliver exceptional support for providers and patients,” said Ela Lourido, vice president and general manager, Biologics by McKesson. “Our Hub services are designed to improve care coordination and reduce time to therapy initiation, supporting better patient outcomes through consistent communication and clinical support, while streamlining access with a cohesive referral workflow and delivering comprehensive patient assistance through a single point of contact.”
About the Therapies
- TAVALISSE® (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
- GAVRETO® (pralsetinib) is a kinase inhibitor indicated for treatment of:
- Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- REZLIDHIA® (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. Rezlidhia has a boxed warning for Differentiation Syndrome – see full prescribing information for complete boxed warning.
Please refer to the full Prescribing Information for complete details on indication, dosing and other relevant product and prescribing information for each individual therapy.
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative and multidisciplinary approach. Putting patients first in all they do, the Biologics’ Pharmacy Elite team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.